Early experience w/SGLT2i in SLE (Prof Petri): 👉Reduction of decline in eGFR after SGLT2i 👉Improvement in RUPCR after SGLT2i BUT observed differences not significant when compared w/prior to starting SGLT2i Small sample size. Longer ffup needed. #ACR23 ABST1490 @RheumNow https://t.co/IhVFacRi0g

You said that CAR-T needs a #RCT in severe #SLE ⁦@RheumNow⁩ ⁦@ACRheum⁩ #ACR23 https://t.co/yilohqz1YE

Watch: Lupus and the Patient Perspective Dr. Kathryn Dao talks with patient advocate Amanda Greene about her patient poster (PP03) on "Lupus with Slime: Improve QOL and Increase ROM in SLE with Slime" at #ACR23. https://t.co/JKU3w7sz4j https://t.co/IWHLJEi0qG

• Lupus and the Patient Perspective | RheumNow

A#1486 @RheumNow #ACR23 STEMI outcomes - SLE v non-SLE 1,000,000 STEMIs, 4000 (0.4% SLE pts) Younger age in SLE grp 61 v 67 yo Increased risk of mortality: aOR 1.3 (CI 1.1-1.5, p<0.05) LOS increased 4.7 v 4.5 d, increased hosp $ SLE: risk of CVD & worse prognostic effect

PAPILUP: HPV in SLE A#1479 #ACR23 @RheumNow 65 SLE pts v healthy v HIV+ 45% not up to date, one only HPV vax High risk HPV in 29% SLE pts, similar to gen pop BUT multiple HR-HPV +abnml cytology higher 15% v 7%, similar to HIV+ Clearance impaired on GCs RF: lupus duration #ACRBest

Petri @jhrheumatology data on SGLT2i in SLE A#1490 #ACR23 @RheumNow Prior to Rx, average annual change in eGFR was -3.1 After starting SGLT2i, average change decr to -0.9 Did not reach signif (p=0.27) Average annual incr in UPCR was 0.4 -> 0.37 on SGLT2i, also not signif https://t.co/TviFyAwXbA